导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.98% | 1771/4773 |
| 近一周 | -1.57% | 539/5461 |
| 近一月 | -3.86% | 2028/5420 |
| 近一季 | -8.44% | 2808/5208 |
| 近半年 | -5.19% | 2773/4919 |
| 近一年 | 5.79% | 1546/4366 |
| 近两年 | 61.95% | 1160/2954 |
| 近三年 | 33.00% | 936/2253 |
| 成立以来 | 55.25% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.35% 1770/4961 |
15.53% 1660/5312 |
- - |
- - |
| 2025 | 25.78% 1685/4813 |
0.36% 1888/3635 |
1.77% 2160/4076 |
23.67% 1522/4524 |
-0.42% 2492/4813 |
| 2024 | 10.84% 1370/3463 |
-1.18% 1193/2808 |
-2.19% 1150/3014 |
13.86% 2089/3129 |
0.72% 1176/3463 |
| 2023 | -8.89% 1070/2656 |
7.09% 605/2280 |
-4.02% 1016/2385 |
-5.59% 1341/2515 |
-6.11% 1628/2655 |
| 2022 | -21.82% 1052/2207 |
-15.23% 1028/1919 |
5.55% 880/2016 |
-13.73% 961/2113 |
1.27% 1315/2208 |
| 2021 | 5.24% 553/1822 |
-4.43% 863/1255 |
10.90% 422/1330 |
-2.09% 554/1466 |
1.42% 937/1822 |
| 2020 | 31.07% 506/1250 |
-5.03% 395/1028 |
16.21% 450/1067 |
9.39% 652/1164 |
8.58% 667/1184 |
| 2019 | 34.51% 401/1092 |
30.47% 246/754 |
-6.99% 536/804 |
1.39% 406/850 |
9.31% 234/918 |
| 2018 | -29.41% 450/834 |
- - |
- - |
- - |
-11.83% 359/691 |
| 2017 | 6.77% 331/714 |
- - |
- - |
- - |
- - |
| 2016 | -15.51% 360/605 |
- - |
- - |
- - |
- - |
| 2015 | 23.44% 99/575 |
- - |
- - |
- - |
- - |
| 2014 | 34.76% 150/237 |
- - |
- - |
- - |
- - |
| 2013 | 3.57% 60/186 |
- - |
- - |
- - |
- - |
| 2012 | -0.71% 123/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 泰信中证200指数 VS. 长安沪深300非周期A(740101) |